Initiation of symptomatic therapy in Parkinson's disease: dopamine agonists versus levodopa
Parkinson's disease (PD) is a chronic progressive neurodegenerative disease and its early treatment is of prime importance. Early treatment of PD has several goals: to increase the patient's quality of life and to have symptomatic benefits, to slow disease progression, and to prevent treatment-related morbidity in the long-term. The treatment strategy in patients with de novo, early-stage PD has numerous facets and should be individually tailored. Levodopa is the gold standard for the symptomatic treatment of PD. However, despite clinical experience with levodopa for more than three decades, there are still unanswered questions about its effect on disease progression and delayed motor complications. There is now an increasing use of dopamine agonists as effective early monotherapy in the treatment of PD. Evidence from randomized-controlled trials has shown that initiating symptomatic therapy with dopamine agonists reduces the risk of development of motor complications and there are also some data suggesting that such treatment may slow disease progression. This article reviews the laboratory and clinical evidence on the therapeutic options in early de novo PD so as to help physicians establish the best-fitting treatment strategy adapted for the individual patient.
Key wordsParkinson's disease treatment dopamine agonists levodopa
Unable to display preview. Download preview PDF.
- 5.Blanchet PJ, Calon F, Martel JC, Bedard PJ, Di Paolo T, Walters RR, Piercey MF (1995) Continuous administration decreases and pulsatile administration increases behavioral sensitivity to a novel dopamine D2 agonist (U-91356A) in MPTP-exposed monkeys. J Pharmacol Exp Ther 272:854–859PubMedGoogle Scholar
- 10.Datla KP, Blunt SB, Dexter D (2001) Chronic L-dopa administration is not toxic to the remaining dopaminergic nigrostriatal neurons, but instead may promote their functional recovery, in rats with partial 6-hydroxydopamine or FeCl3 nigrostriatal lesions. Mov Disord 16:424–434PubMedCrossRefGoogle Scholar
- 11.Djaldetti R, Inzelberg R, Giladi N, Korczyn AD, Peretz-Aharon Y, Rabey MJ, Herishano Y, Honigman S, Badarny S, Melamed E (2002) Oral solution of levodopa ethyl ester for treatment of response fluctuations in patients with advanced Parkinson's disease. Mov Disord 17:297–302PubMedCrossRefGoogle Scholar
- 12.Dupont E, Anderson A, Boqs J, Boisen E, Borgmann R, Helgetveit AC, Kjaer AC, Kristensen TN, Mikkelsen B, Pakkenberg H, Presthus J, Stien R, Worm-Petersen J, Buch D (1996) Sustained-release Madopar HBS compared with standard Madopar in the long-term treatment of de novo parkinsonian patients. Acta Neurol Scand 93:14–20PubMedCrossRefGoogle Scholar
- 22.King DF, Cooper JM, Schapira AHV (2001) Pramipexole protects against MPP + toxicity in SHSY5Y cells by maintaining mitochondrial membrane potential. Neurology 56:A377–A388Google Scholar
- 27.Montastruc JL, Desboeuf K, Lapeyre-Mestre M, Senard JM, Rascol O, Brefel-Courbon C (2001) Long-term mortality results on the randomized controlled study comparing bromocriptine to which levodopa was later added with levodopa alone in previously untreated patients with Parkinson's disease. Mov Disord 16:511–514PubMedCrossRefGoogle Scholar
- 32.Oertel WH, Wolters E, Sampaio C, Gimenez-Roldan S, Bergamasco B, Dujardin M, Grosset DG, Arnold G, Leenders KL, Hundemer HP, Lledo A, Wood A, Frewer P, Schwarz J (2006) Pergolide versus levodopa monotherapy in early Parkinson's disease patients: The PELMOPET study. Mov Disord 21:343–353PubMedCrossRefGoogle Scholar
- 37.Olanow CW, Agid Y, Mizuno Y, Albanese A, Bonuccelli U, Damier P, De Yebenes J, Gershanik O,Guttman M, Grandas F, Hallett M, Hornykiewicz O, Jenner P, Katzenschlager R, Langston WJ, LeWitt P, Melamed E, Mena MA, Michel PP, Mytilineou C, Obeso JA, Poewe W, Quinn N, Raisman-Vozari R, Rajput AH, Rascol O, Sampaio C, Stocchi F (2004) Levodopa in the treatment of Parkinson's disease: current controversies. Mov Disord 19:997–1005PubMedCrossRefGoogle Scholar